A 28-year-old Brisbane woman who was diagnosed with an aggressive form of breast cancer says her message to other young ...

In a new study, patients with early-stage breast cancer linked to BRCA1 and BRCA2 gene mutations showed remarkable survival ...

As a group, carriers of recessive disorders are slightly less healthy and have a reduced chance of having offspring. This disadvantage is greatest for carriers of a recessive gene for intellectual ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Olaparib, which is taken as tablets, is already available on the NHS. A class of cancer drug known as a PARP inhibitor, it ...

In a small study of early-stage breast cancer patients with BRCA gene mutations, researchers from the University of Cambridge ...

Facing down her seventh surgery in a two-year fight with breast cancer, Jill Martin decided to stop and write herself a ...

Researchers conducted a retrospective multicenter cohort study analyzing 575 female patients with BRCA1 or BRCA2 pathogenic ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to Cambridge researchers.

Overall survival (OS) in BRCA -mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.